TSXV:CLAS.H - Post by User
Post by
Red~Oneon Apr 08, 2022 12:59pm
122 Views
Post# 34588358
Nope wrong again
Nope wrong again Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
June 1, 2021
SAN FRANCISCO, CA and TORONTO, ON — (June 1, 2021) – Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has entered into an agreement (the “Debt Forgiveness Agreement”) with the former shareholders of Talent Biotechs Ltd. (the “Talent Shareholders”), under which Claritas will transfer all assets of its program developing cannabidiol for the prevention and treatment of graft versus host disease (the “GVHD Program”) to the Talent Shareholders in exchange for forgiveness of debt and contingent liabilities.